Abstract:11526 Background: Tumor necrosis rate after neoadjuvant therapy is one of the strongest predictors of long-term outcome for patients with osteosarcoma. Patients with good response (tumor necrosis rate ≥90%) have a substantially better survival than those with poor response (tumor necrosis rate < 90%), with 5-year overall survival of 75-80% and 55-65%, respectively. However, treatments for osteosarcoma have not yet shown much progress since the introduction of perioperative chemotherapy in 1970s. New neoadjuvant combinations are required to explored for osteosarcoma. Methods: In this phase II trial (NCT04294511), patients aged 14-65 years with histopathologically confirmed osteosarcoma and Eastern Cooperative Oncology Group performance status of 0-1 received three 21-day cycles of neoadjuvant regimen (camrelizumab 200 mg on day 1 of each cycle; doxorubicin 37.5 mg/m 2 or liposomal doxorubicin 25 mg/m 2 on days 1-2 of cycles 1 and 3; cisplatin 100 mg/m 2 on day 2 of cycles 1 and 3; methotrexate 8-12 g/m 2 on day 12 of cycle 1; and ifosfamide 3 g/m 2 on days 1-4 of cycle 2). Surgery was scheduled 12-14 days after neoadjuvant therapy. Two weeks after surgery, patients received 6 cycles of adjuvant therapy (camrelizumab 200 mg on day 1 of each cycle; doxorubicin 37.5 mg/m 2 or liposomal doxorubicin 25 mg/m 2 on days 9-10 of cycles 1, 3, and 5; cisplatin 100 mg/m 2 on day 10 of cycles 1, 3, and 5; methotrexate 8-12 g/m 2 on day 2 of cycles 1, 3, and 5; and ifosfamide 3 g/m 2 on days 1-4 of cycles 2, 4, and 6). The primary endpoint was good response (tumor necrosis rate ≥90%) rate after neoadjuvant therapy. Results: A total of 86 patients were screened and 75 patients signed informed consent from December 2019 to June 2022. By the data cutoff date on December, 2022, 8 patients did not complete neoadjuvant therapy and 2 patients refused surgery. 65 patients completed neoadjuvant therapy, one patient had disease progression before surgery, 64 received surgical resection and adjuvant therapy, and 44 completed adjuvant therapy. Thirty-one (48.4%, 95%CI: 36.6%-60.4%) of 64 patients showed good response. The most common grade 3-4 adverse events were decreased platelet count (44.0%), decreased white blood cell (37.3%), decreased neutrophil count (29.3%), oral mucositis (14.7%), increased alanine aminotransferase (12.0%), and increased aspartate aminotransferase (10.7%). Conclusions: Camrelizumab combined with doxorubicin, cisplatin, methotrexate and ifosfamide in the perioperative treatment of osteosarcoma patients were safe and tolerable. Postoperative good response rate was similar to previously reported results. Survival follow-up is still ongoing to analyze the effect of perioperative immunotherapy combined with chemotherapy on long-term outcomes of patients with osteosarcoma. Clinical trial information: NCT04294511 .

Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma

Figure S1 from Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study

Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft tissue sarcoma: a prospective, single-arm phase II study

Pegylated liposomal doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma

Phase I study of pegylated liposomal doxorubicin in combination with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory sarcoma and other malignant solid tumors.

Pegylated Liposomal Doxorubicin in Partially Platinum-Sensitive, Platinum-Resistant, or Platinum-Refractory Ovarian Cancer: a Prospective Study

Clinical study of high dose MTX combined with cisplatin in the treatment of osteosarcoma

The Preliminary Report of a Randomized Controlled Multicenter Study of First-Line Chemotherapy Regimen Combined with Angiogenesis Inhibitor for Osteosarcoma of the Extremities

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.

Evaluation of Pirarubicin–cisplatin Chemotherapy in the Treatment for Refractory and Recurrent High-Grade Osteosarcoma: Experience of a Single Institute

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors

ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.

Pegylated liposomal doxorubicin (Duomeisu ® ) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

Cisplatin-Loaded Poly(L-Glutamic Acid)-G-Methoxy Poly(Ethylene Glycol) Nanoparticles As A Potential Chemotherapeutic Agent Against Osteosarcoma

Pegylated Liposomal Doxorubicin As a Single Agent or As Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer

Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.

High-Dose Methotrexate (HD-MTX) Used As an Adjunct with Other Chemotherapeutics for the Treatment of Osteosarcoma

Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways

Efficacy of second-line chemotherapy for advanced osteosarcoma

Comparison of Pemetrexed Plus Cisplatin with Gemcitabine Plus Docetaxel in Refractory/metastatic Osteosarcoma: Clinical Outcomes from a Retrospective Database Monitored in a Single Institute